10-QPeriod: Q3 FY2020

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2020

Filed October 29, 2020For Securities:IDXX

Summary

IDEXX Laboratories Inc. reported strong financial results for the third quarter of 2020, reflecting a significant rebound in its Companion Animal Group (CAG) business following initial COVID-19 related disruptions. Total revenue increased by 19.2% year-over-year to $721.8 million, driven by robust organic growth of 17.8%. The CAG segment, which represents the majority of revenue, saw a 19.7% increase, fueled by strong demand for recurring diagnostic revenues, including consumables and reference laboratory services, as veterinary visits recovered. The company also benefited from its OPTI COVID-19 PCR test, contributing to a substantial 129.5% revenue increase in its 'Other' segment. While the Water segment experienced a slight decline, the Livestock, Poultry, and Dairy (LPD) segment showed solid growth. The company maintained healthy profitability with a gross profit margin of 58.5% and a significant increase in operating income. IDEXX ended the quarter with a strong cash position and ample liquidity, demonstrating resilience and recovery amidst the ongoing pandemic.

Financial Highlights

54 data points
Beta

Revenue

$721.79M

58.5% Gross Margin

Net Income

$146.32M

20.3% Net Margin

EPS (Diluted)

$1.69

Total Assets

$2.05B

Cash & Equivalents

$175.59M

Free Cash Flow

$173.91M

Financial Statements
Beta
Revenue$721.79M
Cost of Revenue$299.18M
Gross Profit$422.61M
R&D Expenses$37.52M
Operating Income$171.86M
Interest Expense$8.11M
Net Income$146.32M
EPS (Basic)$1.71
EPS (Diluted)$1.69
Shares Outstanding (Basic)85.31M
Shares Outstanding (Diluted)86.69M

Key Highlights

  • 1Total revenue for the third quarter of 2020 increased by 19.2% to $721.8 million, with organic revenue growth of 17.8%.
  • 2Companion Animal Group (CAG) revenue grew by 19.7% to $638.0 million, driven by a strong recovery in recurring diagnostic revenues as veterinary visits rebounded.
  • 3Gross profit margin improved to 58.5% from 57.0% in the prior year's quarter, indicating improved operational efficiency and favorable product mix.
  • 4Operating income significantly increased by 22.9% to $171.9 million, demonstrating strong operating leverage.
  • 5The company's 'Other' segment saw a substantial revenue increase of 129.5%, primarily due to the contribution of the new OPTI COVID-19 PCR test.
  • 6Cash and cash equivalents increased substantially to $175.6 million from $90.3 million at the end of 2019, indicating a strong liquidity position.
  • 7The company maintained compliance with its debt covenants, with a healthy debt-to-Adjusted EBITDA ratio of 0.96.

Frequently Asked Questions

The COVID-19 pandemic had a mixed impact. While initially causing disruptions, particularly in the early stages of the quarter, IDEXX experienced a strong rebound, especially in its Companion Animal Group (CAG) as veterinary visits recovered. The pandemic also spurred demand for IDEXX's OPTI COVID-19 PCR test, which significantly boosted revenue in the 'Other' segment. The Water segment saw a slight decline due to reduced non-compliance testing.

The primary driver was the strong performance of the Companion Animal Group (CAG), with a 19.7% revenue increase. This was fueled by recovering veterinary visit volumes, increased demand for recurring diagnostic revenues such as consumables and reference laboratory services, and the successful launch of the OPTI COVID-19 PCR test. The Livestock, Poultry, and Dairy (LPD) segment also contributed positively.

IDEXX Laboratories demonstrated improved financial health. Cash and cash equivalents significantly increased to $175.6 million from $90.3 million at the end of 2019. The company also expanded its credit facility to $1 billion and issued $200 million in senior notes, providing ample liquidity. The debt-to-Adjusted EBITDA ratio remained healthy at 0.96, indicating strong solvency.

The report indicates a strong recovery and positive momentum, particularly in the CAG segment, driven by sustained demand for veterinary diagnostics. The contribution from the OPTI COVID-19 PCR test provides an additional growth avenue. While acknowledging ongoing pandemic-related uncertainties, the company's financial resilience and strategic initiatives suggest a positive outlook for continued growth and profitability.